Drug Discovery & Pharmaceuticals

RSS

Promega Plasmid Collection, available through Addgene, equips industry and academic researchers with powerful bioluminescent assays that provide deeper insights into endogenous cellular biology

Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, today announced a strategic partnership with Promega to expand Addgene’s vast plasmid repository with the launch of the Promega Plasmid Collection.

From Promega Corporation 31 Jul 2025

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

29 Jul 2025

New model predicts mRNA protein production, accelerating drug and vaccine discovery

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types. The new advance, developed through an academic-industrial partnership between The University of Texas at Austin and Sanofi, helps predict how much protein cells will produce, which can minimize the need for trial-and-error experimentation, accelerating the next generation of mRNA therapeutics.

26 Jul 2025

Researchers pinpoint PRMT5 as a promising target for cancer drugs

A potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research Institute's Cancer Research Center in Washington, D.C.

26 Jul 2025

New collaborative effort harnesses AI to drive ALS drug discovery in Louisiana

Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.

23 Jul 2025

PhoreMost demonstrates new approach to rationalize molecular glue drug discovery

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders.

22 Jul 2025

AI turns old diabetes drug Halicin into a potent weapon against superbugs

Researchers found that Halicin, an AI-identified drug, effectively inhibited most multidrug-resistant bacteria except Pseudomonas aeruginosa. The study highlights Halicin’s broad-spectrum antibacterial potential and the transformative role of artificial intelligence in antibiotic discovery.

20 Jul 2025

Ohio State chemists unlock easier path to develop key drug components

Chemists have developed a novel way to generate a variety of highly useful chemical building blocks by harnessing metal carbenes, suggests new research.

18 Jul 2025

Researchers unveil drug complex that makes cancer cells self-report to immune system

Two junior research groups at Ruhr University Bochum, Germany, have developed a drug complex that kills cancer cells in such a clever manner that they raise a red flag as they die. They signal to the immune system that something is seriously wrong with this type of cell.

18 Jul 2025

Targeting amino acid networks could lead to more precise medicines

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like bricks that communicate with each other within a structure.

16 Jul 2025

Optogenetic platform enables precise discovery of anti-aging therapeutics

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases.

16 Jul 2025

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine ("Insilico"), a clinical-stage biotechnology company driven by generative AI, focused on rentosertib (ISM001-055), a novel TNIK inhibitor discovered using Insilico's generative AI approach, in development for the treatment of IPF.

16 Jul 2025

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in preclinical models. This approach not only inhibited cancer cell migration and invasion but also showed strong potential for safer, more precise lung cancer therapy.

14 Jul 2025

Vanderbilt and Parse Biosciences team up to develop antibody treatments for measles

Vanderbilt University Medical Center and Parse Biosciences, an innovator in single-cell sequencing, are collaborating on a new treatment to help unvaccinated measles victims, as the U.S. measles outbreak has now reached its highest case count in 30 years.

8 Jul 2025

Biosynth expands Berlin site with a new commercial bioconjugation suite

Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site.

7 Jul 2025

Innovative approach for the development of next-generation cancer therapies targeting FGFR2/3

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers.

4 Jul 2025

Optibrium partners with TalTech on EU-funded PhD program to advance sustainable drug discovery

Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with TalTech (Tallinn University of Technology) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.

2 Jul 2025

Fidelio Capital partners with Alphalyse to accelerate the global roll-out of LC-MS host cell protein analytics

Alphalyse, a fast-growing Danish specialist contract research organization (CRO) that has developed GMP‑validated liquid‑chromatography mass‑spectrometry (LC‑MS) assays for host‑cell‑protein (HCP) impurity testing in biologic drugs, today announces that Fidelio Capital has acquired a majority stake in the company.

From Alphalyse A/S 2 Jul 2025

Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.

25 Jun 2025

How a novel reaction in E. coli helps recycle plastic into paracetamol

Researchers have demonstrated that E. coli can perform a biocompatible Lossen rearrangement, enabling phosphate-catalysed conversion of synthetic substrates into valuable compounds. This approach allows engineered bacteria to upcycle PET plastic waste into paracetamol, highlighting a novel intersection of chemistry and biotechnology.

24 Jun 2025

Drug Discovery & Pharmaceuticals

Promega Plasmid Collection, available through Addgene, equips industry and academic researchers with powerful bioluminescent assays that provide deeper insights into endogenous cellular biology

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

New model predicts mRNA protein production, accelerating drug and vaccine discovery

Researchers pinpoint PRMT5 as a promising target for cancer drugs

New collaborative effort harnesses AI to drive ALS drug discovery in Louisiana

PhoreMost demonstrates new approach to rationalize molecular glue drug discovery

AI turns old diabetes drug Halicin into a potent weapon against superbugs

Ohio State chemists unlock easier path to develop key drug components

Researchers unveil drug complex that makes cancer cells self-report to immune system

Targeting amino acid networks could lead to more precise medicines

Optogenetic platform enables precise discovery of anti-aging therapeutics

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Vanderbilt and Parse Biosciences team up to develop antibody treatments for measles

Biosynth expands Berlin site with a new commercial bioconjugation suite

Innovative approach for the development of next-generation cancer therapies targeting FGFR2/3

Optibrium partners with TalTech on EU-funded PhD program to advance sustainable drug discovery

Fidelio Capital partners with Alphalyse to accelerate the global roll-out of LC-MS host cell protein analytics

Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery

How a novel reaction in E. coli helps recycle plastic into paracetamol

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Latest Life Science News